Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections

PD Tamma, EL Heil, JA Justo… - Clinical infectious …, 2024 - academic.oup.com
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …

PD Tamma, SL Aitken, RA Bonomo… - Clinical infectious …, 2022 - academic.oup.com
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …

Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem …

PD Tamma, SL Aitken, RA Bonomo… - Clinical Infectious …, 2022 - academic.oup.com
Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …

Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility …

P Gaibani, T Giani, F Bovo, D Lombardo, S Amadesi… - Antibiotics, 2022 - mdpi.com
Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors

J Brem, T Panduwawala, JU Hansen, J Hewitt… - Nature Chemistry, 2022 - nature.com
Carbapenems are vital antibiotics, but their efficacy is increasingly compromised by metallo-
β-lactamases (MBLs). Here we report the discovery and optimization of potent broad …

Call for next-generation drugs that remove the uptake barrier to combat antibiotic resistance

B Peng, H Li, X Peng - Drug Discovery Today, 2023 - Elsevier
Existing antibacterial agents can be categorized into two generations, but bacterial
insensitivity towards both of these classes poses a serious public health challenge …

Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use

D Carcione, C Siracusa, A Sulejmani, V Leoni, J Intra - Antibiotics, 2021 - mdpi.com
The β-lactams have a central place in the antibacterial armamentarium, but the increasing
resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the …

Impact of acquired broad-spectrum β-lactamases on susceptibility to cefiderocol and newly developed β-lactam/β-lactamase inhibitor combinations in Escherichia coli …

L Poirel, JM Ortiz de la Rosa, M Sadek… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
The ability of broad-spectrum β-lactamases to reduce the susceptibility to ceftazidime-
avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam, meropenem …

Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales

KS Kaye, T Naas, JM Pogue, GM Rossolini - Infectious Diseases and …, 2023 - Springer
Carbapenem-resistant Enterobacterales (CRE) remain a significant public health threat,
and, despite recent approvals, new antibiotics are needed. Severe infections caused by …

Emergence of ceftazidime-and avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Pseudomonas aeruginosa in China

Y Zhu, J Chen, H Shen, Z Chen, Q Yang, J Zhu, X Li… - Msystems, 2021 - Am Soc Microbiol
Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-
PA) has been reported sporadically. However, epidemiological and antimicrobial …